Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1. Hand-held Fan Airflow Stimulation Relieves Dyspnea in Lung Cancer Patients. (PubMed)

Hand-held Fan Airflow Stimulation Relieves Dyspnea in Lung Cancer Patients. The main symptom of lung cancer is dyspnea which can lead to depression, anxiety, limited independent activities, and decreased quality of life. The purpose of this study was to identify the effect of airflow stimulation from a hand-held fan as nonpharmacological palliative intervention on dyspnea in patients with lung cancer.This study used open, randomized, controlled, crossover trial design involved 21 participants (...) . Diaphragmatic breathing technique was used in control arm.Wilcoxon test result showed that airflow stimulation significantly influenced dyspnea scale (P = 0.003) and respiratory rate (RR) (P = 0.008). Combination of airflow stimulation and diaphragmatic breathing can lower both dyspnea scale and RR significantly (P < 0.0001).This combination can be applied on nonhypoxemic dyspneic lung cancer patients.

Full Text available with Trip Pro

2019 Asia-Pacific journal of oncology nursing Controlled trial quality: uncertain

2. Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group

Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group Low-dose computed tomography (LDCT) screening detects early-stage lung cancer and reduces mortality. We proposed a sequential approach targeted to a high-risk group as a potentially efficient screening strategy.LungSEARCH was a national multicentre randomised trial (...) . Current/ex-smokers with mild/moderate chronic obstructive pulmonary disease (COPD) were allocated (1:1) to have 5 years surveillance or not. Screened participants provided annual sputum samples for cytology and cytometry, and if abnormal were offered annual LDCT and autofluorescence bronchoscopy (AFB). Those with normal sputum provided annual samples. The primary end-point was the percentage of lung cancers diagnosed at stage I/II (nonsmall cell) or limited disease (small cell).1568 participants were

2019 EvidenceUpdates

3. Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Dacomitinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A19-39 Dacomitinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-39 Version 1.0 Dacomitinib (non-small cell lung cancer) 30 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dacomitinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

4. Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma

Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

5. Atezolizumab (Tecentriq) - metastatic non-squamous non-small cell lung cancer (NSCLC)

Atezolizumab (Tecentriq) - metastatic non-squamous non-small cell lung cancer (NSCLC) Published 09 December 2019 1 Statement of advice SMC2254 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) Roche Products Ltd 8 November 2019 ADVICE: in the absence of a submission from the holder of the marketing authorisation atezolizumab (Tecentriq®) is not recommended for use within NHSScotland. Indication under review: In combination with nab-paclitaxel and carboplatin for the first (...) -line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium

2019 Scottish Medicines Consortium

6. Atezolizumab (Tecentriq) - non-squamous non-small cell lung cancer (NSCLC)

Atezolizumab (Tecentriq) - non-squamous non-small cell lung cancer (NSCLC) 1 Published 11 November 2019 1 SMC2208 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) Roche Products Ltd 04 October 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under (...) the end of life medicine process: atezolizumab (Tecentriq ® ) is not recommended for use within NHSScotland. Indication under review: In combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC, atezolizumab in combination with bevacizumab, paclitaxel and carboplatin

2019 Scottish Medicines Consortium

7. Dacomitinib (Vizimpro) - non-small cell lung cancer (NSCLC)

Dacomitinib (Vizimpro) - non-small cell lung cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September

2019 Health Canada - Drug and Health Product Register

8. Recommendations for Prophylactic Cranial Irradiation and Consolidative Radiation for Patients with Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance

Recommendations for Prophylactic Cranial Irradiation and Consolidative Radiation for Patients with Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance Guideline Endorsement 7-13-2 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Recommendations for Prophylactic Cranial Irradiation and Consolidative Radiation for Patients with Small Cell Lung Cancer: Endorsement of the 2019 National (...) Institute for Health and Care Excellence Guidance M. Taremi, E.T. Vella, S. Cheng, P.M. Ellis, R. Goffin, A. Louie, R. MacRae, Y.C. Ung, and the Lung Cancer Disease Site Group Report Date: November 11, 2019 This document describes the CCO-Lung Cancer Disease Site Group endorsement of the recommendations for prophylactic cranial irradiation and consolidative radiation for patients with small cell lung cancer from © NICE [2019] Lung cancer: diagnosis and management. The original publication is available

2019 Cancer Care Ontario

9. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. (PubMed)

Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. To compare the efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC).Systematic review and network meta-analysis.PubMed, Embase, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and several

Full Text available with Trip Pro

2019 BMJ

10. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. (PubMed)

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination

2019 Lancet

11. Tecentriq for Small Cell Lung Cancer – Details

Tecentriq for Small Cell Lung Cancer – Details Tecentriq for Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Tecentriq for Small Cell Lung Cancer – Details Tecentriq for Small Cell Lung Cancer – Details Project Number pCODR 10156 Brand Name Tecentriq Generic Name Atezolizumab Strength 60 mg/mL Tumour Type Lung Indication Small Cell Lung Cancer (SCLC) Funding Request For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC

2019 CADTH - Pan Canadian Oncology Drug Review

12. Imfinzi for Non-Small Cell Lung Cancer – Details

Imfinzi for Non-Small Cell Lung Cancer – Details Imfinzi for Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Imfinzi for Non-Small Cell Lung Cancer – Details Imfinzi for Non-Small Cell Lung Cancer – Details Project Number pCODR 10131 Brand Name Imfinzi Generic Name Durvalumab Strength 50 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer Funding Request For the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC

2019 CADTH - Pan Canadian Oncology Drug Review

13. Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details

Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Project Number pCODR 10151 Brand Name Xalkori Generic Name Crizotinib Strength 200 mg & 250 mg Tumour Type Lung Indication ROS1-positive advanced Non-Small Cell Lung (...) Cancer Funding Request As a single agent as first-line treatment for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) Review Status Notification to Implement Issued Pre Noc Submission No NOC Date August 28, 2017 Manufacturer Pfizer Canada Inc. Sponsor Cancer Care Ontario Lung Cancer Drug Advisory Committee Submission Date October 30, 2018 Submission Deemed Complete November 13, 2018 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline ‡ November 13

2019 CADTH - Pan Canadian Oncology Drug Review

14. Vizimpro for Non-Small Cell Lung Cancer – Details

Vizimpro for Non-Small Cell Lung Cancer – Details Vizimpro for Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Vizimpro for Non-Small Cell Lung Cancer – Details Vizimpro for Non-Small Cell Lung Cancer – Details Project Number pCODR 10129 Brand Name Vizimpro Generic Name Dacomitinib Strength 15 mg, 30 mg & 45 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer Funding Request For the first-line treatment of patients with locally advanced or metastatic non (...) ‑small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date February 26, 2019 Manufacturer Pfizer Canada Inc. Sponsor Pfizer Canada Inc. Submission Date September 19, 2018 Submission Deemed Complete October 3, 2018 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ October 3, 2018 Check-point meeting December 4, 2018 pERC Meeting March 21, 2019 Initial

2019 CADTH - Pan Canadian Oncology Drug Review

15. Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details

Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details | CADTH.ca Find the information you need Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Project Number pCODR 10158 Brand Name Mvasi Generic Name Bevacizumab Strength 100 mg and 400 mg Tumour (...) Type Gastrointestinal / Lung Indication Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar Funding Request For first-line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with fluoropyrimidine based chemotherapy / For treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen Review Status Final Biosimilar Dossier Issued Pre

2019 CADTH - Pan Canadian Oncology Drug Review

16. Tagrisso for Non-Small Cell Lung Cancer (first line) – Details

Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Tagrisso for Non-Small Cell Lung Cancer (first line) – Details | CADTH.ca Find the information you need Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Project Number pCODR 10137 Brand Name Tagrisso Generic Name Osimertinib Strength 40 mg and 80 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer (first line) Funding Request For the first-line (...) treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date July 10, 2018 Manufacturer AstraZeneca Canada Inc. Sponsor AstraZeneca Canada Inc. Submission Date May 16, 2018 Submission Deemed Complete May 24, 2018 Submission Type New Indication Prioritization Requested Requested and Not Granted Stakeholder Input Deadline ‡ May

2019 CADTH - Pan Canadian Oncology Drug Review

17. Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details

Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details | CADTH.ca Find the information you need Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Project Number pCODR 10183 Brand Name Lorbrena Generic Name Lorlatinib Tumour Type Lung Indication Non-Small Cell Lung Cancer (NSCLC) Funding Request For the treatment of adult patients with anaplastic (...) lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or alectinib. Review Status Under Review Pre Noc Submission No NOC Date Manufacturer Pfizer Canada ULC Sponsor Pfizer Canada ULC Submission Date June 11, 2019 Submission Deemed Complete June 25, 2019 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ June 25, 2019 Check-point meeting

2019 CADTH - Pan Canadian Oncology Drug Review

18. ALK Inhibitors for Non–Small Cell Lung Cancer

ALK Inhibitors for Non–Small Cell Lung Cancer ALK Inhibitors for Non–Small Cell Lung Cancer | CADTH.ca Find the information you need ALK Inhibitors for Non–Small Cell Lung Cancer ALK Inhibitors for Non–Small Cell Lung Cancer Last updated: February 20, 2019 Project Number: HE0017-000 Product Line: Technology Review Result type: Report Lung cancer is the second-most commonly diagnosed cancer in both men and women, and is the leading cause of cancer deaths in Canada. Rearrangement (...) of the Anaplastic Lymphoma Kinase (ALK) gene drives the development of about 5% of non–small cell lung cancers (NSCLC). Inhibitors of ALK can effectively delay progression of these malignancies and are the treatment of choice in the first-line and subsequent line settings. This drug class is expanding and new products are poised to enter the market. Reviews of the comparative clinical and cost-effectiveness of ALK inhibitors, and of guidelines pertaining to their use, were requested by Canadian decision-makers

2019 CADTH - Technology Review

19. Entrectinib (Rozlytrek) - metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive

Entrectinib (Rozlytrek) - metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive Drug Approval Package: ROZLYTREK U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ROZLYTREK Company: Genentech Application Number: 212725, 212726 Approval Date: 08/15/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2019 FDA - Drug Approval Package

20. Metastatic Non-Small-Cell Lung Cancer

Metastatic Non-Small-Cell Lung Cancer Updated version published 18 September 2019 by the ESMO Guidelines Committee © European Society for Medical Oncology 2019. All rights reserved. 1 CLINICAL PRACTICE GUIDELINES Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † Originally published in 2018 – Ann Oncol (2018) 29 (suppl 4): iv192–iv237 D. Planchard 1 , S. Popat 2 , K. Kerr 3 , S. Novello 4 , E. F. Smit 5 , C. Faivre-Finn 6 , T. S (...) of Cancer Sciences, University of Manchester, Manchester, UK; 7 Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; 8 LungenClinic Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany; 9 Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Antwerp, Belgium; 10 Weill Cornell Medical College, New York, USA; 11 Medical Oncology, Centre Hospitalier Universitaire

2019 European Society for Medical Oncology